Patents by Inventor Romas Kudirka
Romas Kudirka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091370Abstract: The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 10, 2021Publication date: March 21, 2024Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, Romas KUDIRKA, Arthur LEE, Brian SAFINA, Matthew ZHOU
-
Publication number: 20240042050Abstract: The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-phenyl-2-aminobenzazepine derivatives. The invention also provides 8-phenyl-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 10, 2021Publication date: February 8, 2024Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, Romas KUDIRKA, Arthur LEE, Brian SAFINA, Matthew ZHOU
-
Publication number: 20240033370Abstract: The invention provides immunoconjugates of Formula I comprising an anti-PD-L1 antibody linked by conjugation to one or more 8-Cyc-2-aminobenzazepine derivatives. The invention also provides 8-Cyc-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 10, 2021Publication date: February 1, 2024Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin ACKERMAN, Michael N. ALONSO, David DORNAN, Marcin KOWANETZ, Romas KUDIRKA, Arthur LEE, William MALLET, Brian SAFINA, Matthew ZHOU
-
Publication number: 20230338571Abstract: The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: March 6, 2023Publication date: October 26, 2023Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Romas Kudirka, Brian Safina
-
Publication number: 20230293716Abstract: The invention provides immunoconjugates of Formula I comprising a cell-binding agent linked by conjugation to one or more immunostimulatory moieties where the linker is a substrate for elastase. The invention also provides immunostimulant intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: May 7, 2021Publication date: September 21, 2023Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: David DORNAN, Romas KUDIRKA, Brian SAFINA, Matthew ZHOU
-
Publication number: 20230263903Abstract: The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more pyrazoloazepine derivatives. The invention also provides pyrazoloazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: August 12, 2021Publication date: August 24, 2023Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Romas KUDIRKA, Brian SAFINA
-
Publication number: 20230257393Abstract: The invention provides macromolecule-supported compounds of Formula I comprising a macromolecular support linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The invention further provides methods of treating cancer with the macromolecule-supported compounds.Type: ApplicationFiled: October 23, 2020Publication date: August 17, 2023Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Romas KUDIRKA, Brian SAFINA
-
Patent number: 11654199Abstract: The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: GrantFiled: October 23, 2020Date of Patent: May 23, 2023Assignee: BOLT BIOTHERAPEUTICS, INC.Inventors: Romas Kudirka, Brian Safina
-
Publication number: 20220347312Abstract: The invention provides a method for producing an immunoconjugate, the method comprising combining one or more compounds of Formula I and an antibody construct of Formula II to provide the immunoconjugate of Formula III, wherein TA is a therapeutic agent, L is a linker, r is an integer from 1 to 50, Ar is an aromatic moiety comprising a substituent selected from PEG, —SO2CX3, —NR3+, —NO2, —SO3R, —SO2R, —CN, —CX3, —PO3R2, —OPO3R2, and salts thereof, each R independently is H, CX3, or C1-C4 alkyl, each X independently is hydrogen or a halogen, Y is CH2, PEG, or a bond, n is an integer from 1 to 4, and PEG has the formula: —(CH2CH2O)m-(CH2)p—, where p is an integer from 1 to 5 and m is an integer from 2 to 50. The invention also provides an immunoconjugate and a composition of immunoconjugates formed from said method.Type: ApplicationFiled: September 4, 2020Publication date: November 3, 2022Applicant: Bolt Biotherapeutics, Inc.Inventors: Puneet Anand, David Dornan, Romas Kudirka, Richard P. Laura, Arthur Lee, Brian Safina, Matthew Zhou
-
Publication number: 20220347310Abstract: The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more 8-amido-2-aminobenzazepine derivatives. The invention also provides 8-amido-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: September 29, 2020Publication date: November 3, 2022Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Romas KUDIRKA, Brian SAFINA, Matthew ZHOU
-
Publication number: 20220313835Abstract: The invention provides immunoconjugates of Formula (I) comprising an antibody linked by conjugation to one or more aminoquinoline derivatives. The invention also provides aminoquinoline derivative intermediate compositions of Formula (III) comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: September 2, 2020Publication date: October 6, 2022Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Romas KUDIRKA, Brian SAFINA, Matthew ZHOU
-
Publication number: 20220315537Abstract: The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.Type: ApplicationFiled: June 12, 2020Publication date: October 6, 2022Applicant: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin Ackerman, Michael N. Alonso, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou
-
Publication number: 20220226492Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 (“HER2”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: July 21, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220226491Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: July 21, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220195066Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: December 9, 2021Publication date: June 23, 2022Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
-
Publication number: 20220152215Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.Type: ApplicationFiled: March 13, 2020Publication date: May 19, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20220143012Abstract: The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule-supported compounds.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior UniversityInventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
-
Publication number: 20210128744Abstract: The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: October 23, 2020Publication date: May 6, 2021Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Romas Kudirka, Brian Safina
-
Publication number: 20200390899Abstract: The invention provides immunoconjugates of Formula I or III comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The invention also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.Type: ApplicationFiled: June 12, 2020Publication date: December 17, 2020Applicant: BOLT BIOTHERAPEUTICS, INC.Inventors: Shelley Erin Ackerman, Michael N. Alonso, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou
-
Patent number: 7034147Abstract: The present invention provides combinatorial libraries of nucleoside analog compounds and methods of making the libraries. In addition, the present invention provides methods of assaying the libraries for agonists or antagonists of a broad array of targets of therapeutic importance.Type: GrantFiled: May 8, 2003Date of Patent: April 25, 2006Assignee: IRM LLCInventors: Robert Epple, William Greenberg, Romas Kudirka